CN105582382A - 一种用于胆管炎术后护理的药物组合物及其制备方法 - Google Patents
一种用于胆管炎术后护理的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN105582382A CN105582382A CN201610049845.9A CN201610049845A CN105582382A CN 105582382 A CN105582382 A CN 105582382A CN 201610049845 A CN201610049845 A CN 201610049845A CN 105582382 A CN105582382 A CN 105582382A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- cholangitis
- postoperative care
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 42
- 208000003167 cholangitis Diseases 0.000 title claims abstract description 35
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000000474 nursing effect Effects 0.000 title abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 31
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 244000267222 Brasenia schreberi Species 0.000 claims abstract description 27
- 235000006506 Brasenia schreberi Nutrition 0.000 claims abstract description 27
- 239000011858 nanopowder Substances 0.000 claims abstract description 20
- 240000008042 Zea mays Species 0.000 claims abstract description 19
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 19
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 19
- 235000005822 corn Nutrition 0.000 claims abstract description 19
- NGSWKAQJJWESNS-UHFFFAOYSA-N 4-coumaric acid Chemical compound OC(=O)C=CC1=CC=C(O)C=C1 NGSWKAQJJWESNS-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000001368 chlorogenic acid Nutrition 0.000 claims abstract description 11
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 11
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims abstract description 9
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims abstract description 9
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims abstract description 9
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims abstract description 9
- 229940074393 chlorogenic acid Drugs 0.000 claims abstract description 9
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims abstract description 9
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims abstract description 9
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 8
- NGSWKAQJJWESNS-ZZXKWVIFSA-M 4-Hydroxycinnamate Natural products OC1=CC=C(\C=C\C([O-])=O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-M 0.000 claims abstract description 8
- DFYRUELUNQRZTB-UHFFFAOYSA-N Acetovanillone Natural products COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 claims abstract description 8
- LAZPBGZRMVRFKY-HNCPQSOCSA-N Levamisole hydrochloride Chemical compound Cl.C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 LAZPBGZRMVRFKY-HNCPQSOCSA-N 0.000 claims abstract description 8
- 229960003734 levamisole hydrochloride Drugs 0.000 claims abstract description 8
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims abstract description 8
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 8
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 8
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims abstract description 7
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims abstract description 7
- 229960005233 cineole Drugs 0.000 claims abstract description 7
- 238000011084 recovery Methods 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 38
- 239000000843 powder Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 12
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 239000000314 lubricant Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 240000002853 Nelumbo nucifera Species 0.000 claims description 10
- 229930182478 glucoside Natural products 0.000 claims description 10
- 150000008131 glucosides Chemical class 0.000 claims description 10
- 239000011812 mixed powder Substances 0.000 claims description 10
- 238000010298 pulverizing process Methods 0.000 claims description 10
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 9
- 229930182817 methionine Natural products 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 claims description 7
- 101710094902 Legumin Proteins 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 7
- 239000007884 disintegrant Substances 0.000 claims description 7
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 235000019698 starch Nutrition 0.000 claims description 7
- 239000008107 starch Substances 0.000 claims description 7
- 235000004936 Bromus mango Nutrition 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
- 235000014826 Mangifera indica Nutrition 0.000 claims description 6
- 235000009184 Spondias indica Nutrition 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 6
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
- 239000002250 absorbent Substances 0.000 claims description 5
- 230000002745 absorbent Effects 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000013505 freshwater Substances 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 235000021419 vinegar Nutrition 0.000 claims description 5
- 239000000052 vinegar Substances 0.000 claims description 5
- 235000020985 whole grains Nutrition 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 2
- 244000004281 Eucalyptus maculata Species 0.000 claims 1
- 240000007228 Mangifera indica Species 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 235000020265 peanut milk Nutrition 0.000 claims 1
- 239000000341 volatile oil Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 abstract description 22
- 210000000936 intestine Anatomy 0.000 abstract description 17
- 150000001413 amino acids Chemical class 0.000 abstract description 12
- 210000000232 gallbladder Anatomy 0.000 abstract description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 abstract description 11
- 235000019341 magnesium sulphate Nutrition 0.000 abstract description 11
- 210000004185 liver Anatomy 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 206010008635 Cholestasis Diseases 0.000 abstract description 4
- 241000894006 Bacteria Species 0.000 abstract description 3
- 230000007870 cholestasis Effects 0.000 abstract description 3
- 231100000359 cholestasis Toxicity 0.000 abstract description 3
- 206010022678 Intestinal infections Diseases 0.000 abstract description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 abstract 2
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 abstract 2
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 abstract 1
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 abstract 1
- 239000008456 cordacin Substances 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 241000411851 herbal medicine Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940087305 limonene Drugs 0.000 abstract 1
- 235000001510 limonene Nutrition 0.000 abstract 1
- 229940043357 mangiferin Drugs 0.000 abstract 1
- 229940052490 naringin Drugs 0.000 abstract 1
- 229930019673 naringin Natural products 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 150000004676 glycans Chemical class 0.000 description 11
- 229920001282 polysaccharide Polymers 0.000 description 11
- 239000005017 polysaccharide Substances 0.000 description 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 210000000013 bile duct Anatomy 0.000 description 7
- 210000005229 liver cell Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000000941 bile Anatomy 0.000 description 6
- 210000003445 biliary tract Anatomy 0.000 description 6
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 6
- 230000007872 intrahepatic cholestasis Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 241001093152 Mangifera Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 229930192334 Auxin Natural products 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 206010046788 Uterine haemorrhage Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- 239000002363 auxin Substances 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000023852 carbohydrate metabolic process Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 229940097043 glucuronic acid Drugs 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000011987 methylation Effects 0.000 description 4
- 238000007069 methylation reaction Methods 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000002310 reflectometry Methods 0.000 description 4
- 210000005070 sphincter Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960003487 xylose Drugs 0.000 description 4
- 150000000193 1,8-cineol derivatives Chemical class 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- -1 aromatic amino acid Chemical class 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000002279 cholagogic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- CHHHXKFHOYLYRE-STWYSWDKSA-M potassium sorbate Chemical class [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000004514 sphincter of oddi Anatomy 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 201000010312 acute cholangitis Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000000969 egg white Anatomy 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002434 immunopotentiative effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000001114 myogenic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010056375 Bile duct obstruction Diseases 0.000 description 1
- 206010004637 Bile duct stone Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000010013 chronic cholangitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical group O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008812 xiaoyanlidan Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种用于胆管炎术后护理的药物组合物及其制备方法,所述用于胆管炎术后护理的药物组合物是由以下重量份的成分组成:对香豆酸12-30份、柚皮苷15-32份、荷莲豆素10-28份、莼菜提取物10-25份、杧果甙15-26份、赤石脂纳米粉8-18份、柠檬烯12-24份、桉油精16-28份、绿原酸14-20份、盐酸左旋咪唑6-12份、硫酸镁溶液40-80份、玉米浆50-100份、山梨酸钾8-16份、混合氨基酸13-25份。本发明的药物组合物是在西药的基础上加入中草药的有效成分,具有抗菌消炎、抑制肠道感染、预防胆汁淤积的作用,有效调节患者肝脏、胆囊及肠道的功能,改善肌体的各项异常指标从而预防胆管炎的复发并能加快患者术后身体的恢复,本发明药物组合物制备工艺简单,使用方便,有很好的临床意义。
Description
技术领域
本发明涉及外科术后护理用药技术领域,具体是涉及一种用于胆管炎术后护理的药物组合物及其制备方法。
背景技术
胆管炎是一种以胆管炎症为主的胆道炎症,多数是由于胆汁淤积后导致的继发性细菌感染,致病菌主要是革兰阴性杆菌,最常见的是大肠杆菌,细菌通过淋巴道或血道到达胆道,也可从肠道经十二指肠乳头逆行进入胆道。主要分为急性胆管炎和慢性胆管炎,临床症状表现为中上腹不适、胀痛,或呈绞痛发作,进食油腻食物后可加重上腹疼痛,很少有发热和黄疸,腹部体征不明显,可仅有上腹轻压痛,胆囊不肿大。如急性发作,则出现腹痛,寒战高热和黄疸等三联征,还有休克、神经中枢系统受抑制表现,称为Reynolds五联征。急性化脓性胆管炎系胆道梗阻使胆汁淤滞、胆管内压力迅速增高所致胆道急性化脓性感染,急性胆管炎经保守治疗后炎症可以得到控制,但胆管内的原发病因(如肝内外胆管结石,胆道蛔虫症或奥狄括约肌狭窄等)并未解决,胆管内炎症病变转为慢性,使胆管壁增厚。所以临床上常用手术治疗解除胆管梗阻,使胆管压力减低,引流通畅,常见的是切开胆管取除结石或蛔虫,并作T形管引流,奥狄括约肌狭窄,可作括约肌成形术;胆总管下端梗阻可作胆总管十二指肠吻合或胆管空肠Roux-y吻合等胆肠内引流术。肝内胆管狭窄者,须彻底了解其病理变化,解除其梗阻原因,如作肝内胆管狭窄段切开,并清除肝内结石,然后作Roux-y式胆管空肠吻合,奥狄括约肌成形和胆管十二指肠吻合术后容易发生逆流性胆管炎等。
手术治疗后的护理也是很关键的,不仅要能消除感染,还需要从多方面来预防胆管炎复发,大剂量的广谱类抗生素的联合应用对术前控制感染是很重要的,但是术后肌体抵抗能力差,身体虚弱,无法抵抗大量抗生素带来的副作用,因此需要一种药物在胆管炎术后护理中不仅能有效的抗菌消炎,还能促进肌体恢复并且预防胆管炎症复发。
发明内容
本发明解决的技术问题是,提供一种用于胆管炎术后护理的药物组合物及其制备方法。
本发明的技术方案是,一种用于胆管炎术后护理的药物组合物,是由以下重量份的成分组成:对香豆酸12-30份、柚皮苷15-32份、荷莲豆素10-28份、莼菜提取物10-25份、杧果甙15-26份、赤石脂纳米粉8-18份、柠檬烯12-24份、桉油精16-28份、绿原酸14-20份、盐酸左旋咪唑6-12份、硫酸镁溶液20-40份、玉米浆50-100份、山梨酸钾8-16份、混合氨基酸13-25份。
进一步的,所述的莼菜提取物制备方法为:将新鲜的莼菜清洗干净后粉碎,置于闪式提取器中,加入5-8倍量的质量浓度为55-65%乙醇溶液,进行闪式提取,将得到的提取液静置8-12h后,经过大孔吸附树脂过滤,将滤液减压浓缩回收乙醇后制得浸膏,再将浸膏使用喷雾干燥塔干燥,即得到莼菜提取物,莼菜中含有淀粉、蛋白质、脂肪、碳水化合物,其中大多为多糖、钙、磷、铁、铜、钾等矿物质元素,以及人体必需的多种氨基酸,对促进人体生长,增加胃液分泌,滋养血液,安神养心,防止肝脏损坏等,均有一定疗效。莼菜多糖是一种酸性果多糖,由岩藻糖、阿拉伯糖、木糖、甘露糖,半乳糖和葡萄糖醛酸组成,是一种较好的免疫促进剂。
进一步的,所述赤石脂纳米粉制备方法为:将赤石脂清洗干净,除去杂质,打碎后研磨成细粉,加入食醋搅拌和匀,搓成直径2-3cm的条状物,再切成8-10cm长的小段,常温凉干后置于炉火或坩锅内煅红透,再粉碎后冷却,置于纳米粉碎机粉碎至50-100nm的细粉,即得到赤石脂纳米粉,主要成分是四水硅酸铝,具有涩肠,止血,生肌敛疮之功效,常用于久泻久痢,大便出血,崩漏带下,可以有效扩张肠道活性。
进一步的,所述混合氨基酸是由蛋氨酸、赖氨酸、苯丙氨酸按照重量比1:3:5组成的混合物,蛋氨酸可以促进肝细胞膜磷脂甲基化,可以减少肝细胞内胆汁的淤积,加强了解毒作用,有利于肝细胞恢复正常生理功能,抵抗各种原因引起的肝内胆汁淤积病毒感染、妊娠和长期肠道外营养都有可能导致肝内胆汁淤积;赖氨酸能促进人体发育、增强免疫功能,并有提高中枢神经组织功能的作用;苯丙氨酸属芳香族氨基酸,在体内大部分经苯丙氨酸羟化酶催化作用氧化成酪氨酸,并与酪氨酸一起合成重要的神经递质和激素,参与机体糖代谢和脂肪代谢;这三种氨基酸混合后能快速的促进肌体恢复,并且增强免疫能力。
进一步的,所述玉米浆中的固体物质含量为50-70%,玉米浆中含有丰富的可溶性蛋白、生长素和一些前体物质。
进一步的,所述硫酸镁溶液浓度为3-5%,硫酸镁水溶液到达肠腔后,具有一定渗透压,使肠内水分不被肠壁吸收,肠内保有大量水分,能机械地刺激肠的蠕动,同时会刺激十二指肠粘膜,反射性地引起总胆管括约肌松弛、胆囊收缩,从而促进胆囊排空,有利胆之功效。
一种用于胆管炎术后护理的药物组合物制备方法为:
步骤一:给所述重量组份的玉米浆和硫酸镁溶液混合,再加入所述重量组份的莼菜提取物、赤石脂纳米粉,搅拌均匀,喷雾干燥后得到混合粉,备用,这样使莼菜提取物、赤石脂纳米粉、硫酸镁混合均匀,避免不均匀导致的局部有效成分含量过大;
步骤二:将所述重量组份的对香豆酸、柚皮苷、荷莲豆素、杧果甙、柠檬烯、桉油精、绿原酸、盐酸左旋咪唑、山梨酸钾、混合氨基酸混合后,再加入步骤一制备的混合粉,置于搅拌机以120-150r/min,搅拌30-45min,即制得用于胆管炎术后护理的药物组合物。
一种用于胆管炎术后护理的药物组合物加入辅料:润滑剂、崩解剂,通过制粒、干燥、整粒、混合、压片、包装制成片剂。所述的润滑剂是微粉硅胶、硬脂酸镁、滑石粉的一种或者几种混合。所述的崩解剂是羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠的一种或者几种混合。
本发明的有益效果是:在西药的基础上加入中草药的有效成分,具有抗菌消炎、抑制肠道感染、预防胆汁淤积的作用,有效调节患者肝脏、胆囊及肠道的功能,补充人体所需的氨基酸能够增强营养,增强人体细胞组织的活性,调节人体免疫机能,改善肌体的各项异常指标从而预防胆管炎的复发并能加快患者术后身体的恢复,本发明药物组合物制备工艺简单,使用方便,有很好的临床意义。
具体实施方式
实施例1:
一种用于胆管炎术后护理的药物组合物的片剂,主要是由以下重量份的成分组成:对香豆酸12份、柚皮苷15份、荷莲豆素10份、莼菜提取物10份、杧果甙15份、赤石脂纳米粉8份、柠檬烯12份、桉油精16份、绿原酸14份、盐酸左旋咪唑6份、硫酸镁溶液20份、玉米浆50份、山梨酸钾8份、混合氨基酸13份;还包括辅料:润滑剂18份、崩解剂26份。
其中,所述的莼菜提取物制备方法为:将新鲜的莼菜清洗干净后粉碎,置于闪式提取器中,加入5倍量的质量浓度为55%乙醇溶液,进行闪式提取,将得到的提取液静置8h后,经过大孔吸附树脂过滤,将滤液减压浓缩回收乙醇后制得浸膏,再将浸膏使用喷雾干燥塔干燥,即得到莼菜提取物,莼菜中含有淀粉、蛋白质、脂肪、碳水化合物,其中大多为多糖、钙、磷、铁、铜、钾等矿物质元素,以及人体必需的多种氨基酸,对促进人体生长,增加胃液分泌,滋养血液,安神养心,防止肝脏损坏等,均有一定疗效。莼菜多糖是一种酸性果多糖,由岩藻糖、阿拉伯糖、木糖、甘露糖,半乳糖和葡萄糖醛酸组成,是一种较好的免疫促进剂。所述赤石脂纳米粉制备方法为:将赤石脂清洗干净,除去杂质,打碎后研磨成细粉,加入食醋搅拌和匀,搓成直径2cm的条状物,再切成8cm长的小段,常温凉干后置于炉火或坩锅内煅红透,再粉碎后冷却,置于纳米粉碎机粉碎至50nm的细粉,即得到赤石脂纳米粉,主要成分是四水硅酸铝,具有涩肠,止血,生肌敛疮之功效,常用于久泻久痢,大便出血,崩漏带下,可以有效扩张肠道活性。所述混合氨基酸是由蛋氨酸、赖氨酸、苯丙氨酸按照重量比1:3:5组成的混合物,蛋氨酸可以促进肝细胞膜磷脂甲基化,可以减少肝细胞内胆汁的淤积,加强了解毒作用,有利于肝细胞恢复正常生理功能,抵抗各种原因引起的肝内胆汁淤积病毒感染、妊娠和长期肠道外营养都有可能导致肝内胆汁淤积;赖氨酸能促进人体发育、增强免疫功能,并有提高中枢神经组织功能的作用;苯丙氨酸属芳香族氨基酸,在体内大部分经苯丙氨酸羟化酶催化作用氧化成酪氨酸,并与酪氨酸一起合成重要的神经递质和激素,参与机体糖代谢和脂肪代谢;这三种氨基酸混合后能快速的促进肌体恢复,并且增强免疫能力。所述玉米浆中的固体物质含量为50%,玉米浆中含有丰富的可溶性蛋白、生长素和一些前体物质。所述硫酸镁溶液浓度为3%,硫酸镁水溶液到达肠腔后,具有一定渗透压,使肠内水分不被肠壁吸收,肠内保有大量水分,能机械地刺激肠的蠕动,同时会刺激十二指肠粘膜,反射性地引起总胆管括约肌松弛、胆囊收缩,从而促进胆囊排空,有利胆之功效。
一种用于胆管炎术后护理的药物组合物制备方法为:
步骤一:给所述重量组份的玉米浆和硫酸镁溶液混合,再加入所述重量组份的莼菜提取物、赤石脂纳米粉,搅拌均匀,喷雾干燥后得到混合粉,备用,这样使莼菜提取物、赤石脂纳米粉、硫酸镁混合均匀,避免不均匀导致的局部有效成分含量过大;
步骤二:将所述重量组份的对香豆酸、柚皮苷、荷莲豆素、杧果甙、柠檬烯、桉油精、绿原酸、盐酸左旋咪唑、山梨酸钾、混合氨基酸混合后,再加入步骤一制备的混合粉,置于搅拌机以120r/min,搅拌30min,即制得用于胆管炎术后护理的药物组合物;
步骤三:给步骤二制备的药物组合物加入辅料:润滑剂、崩解剂,通过制粒、干燥、整粒、混合、压片、包装制成片剂,所述的润滑剂是微粉硅胶,所述的崩解剂是羧甲基淀粉钠。
实施例2:
一种用于胆管炎术后护理的药物组合物的片剂,主要是由以下重量份的成分组成:对香豆酸21份、柚皮苷23.5份、荷莲豆素19份、莼菜提取物17.5份、杧果甙20.5份、赤石脂纳米粉13份、柠檬烯18份、桉油精22份、绿原酸17份、盐酸左旋咪唑9份、硫酸镁溶液30份、玉米浆75份、山梨酸钾12份、混合氨基酸19份。
其中,所述的莼菜提取物制备方法为:将新鲜的莼菜清洗干净后粉碎,置于闪式提取器中,加入6.5倍量的质量浓度为60%乙醇溶液,进行闪式提取,将得到的提取液静置10h后,经过大孔吸附树脂过滤,将滤液减压浓缩回收乙醇后制得浸膏,再将浸膏使用喷雾干燥塔干燥,即得到莼菜提取物,莼菜中含有淀粉、蛋白质、脂肪、碳水化合物,其中大多为多糖、钙、磷、铁、铜、钾等矿物质元素,以及人体必需的多种氨基酸,对促进人体生长,增加胃液分泌,滋养血液,安神养心,防止肝脏损坏等,均有一定疗效。莼菜多糖是一种酸性果多糖,由岩藻糖、阿拉伯糖、木糖、甘露糖,半乳糖和葡萄糖醛酸组成,是一种较好的免疫促进剂。所述赤石脂纳米粉制备方法为:将赤石脂清洗干净,除去杂质,打碎后研磨成细粉,加入食醋搅拌和匀,搓成直径2.5cm的条状物,再切成9cm长的小段,常温凉干后置于炉火或坩锅内煅红透,再粉碎后冷却,置于纳米粉碎机粉碎至75nm的细粉,即得到赤石脂纳米粉,主要成分是四水硅酸铝,具有涩肠,止血,生肌敛疮之功效,常用于久泻久痢,大便出血,崩漏带下,可以有效扩张肠道活性。所述混合氨基酸是由蛋氨酸、赖氨酸、苯丙氨酸按照重量比1:3:5组成的混合物,蛋氨酸可以促进肝细胞膜磷脂甲基化,可以减少肝细胞内胆汁的淤积,加强了解毒作用,有利于肝细胞恢复正常生理功能,抵抗各种原因引起的肝内胆汁淤积病毒感染、妊娠和长期肠道外营养都有可能导致肝内胆汁淤积;赖氨酸能促进人体发育、增强免疫功能,并有提高中枢神经组织功能的作用;苯丙氨酸属芳香族氨基酸,在体内大部分经苯丙氨酸羟化酶催化作用氧化成酪氨酸,并与酪氨酸一起合成重要的神经递质和激素,参与机体糖代谢和脂肪代谢;这三种氨基酸混合后能快速的促进肌体恢复,并且增强免疫能力。所述玉米浆中的固体物质含量为60%,玉米浆中含有丰富的可溶性蛋白、生长素和一些前体物质。所述硫酸镁溶液浓度为4%,硫酸镁水溶液到达肠腔后,具有一定渗透压,使肠内水分不被肠壁吸收,肠内保有大量水分,能机械地刺激肠的蠕动,同时会刺激十二指肠粘膜,反射性地引起总胆管括约肌松弛、胆囊收缩,从而促进胆囊排空,有利胆之功效。
一种用于胆管炎术后护理的药物组合物制备方法为:
步骤一:给所述重量组份的玉米浆和硫酸镁溶液混合,再加入所述重量组份的莼菜提取物、赤石脂纳米粉,搅拌均匀,喷雾干燥后得到混合粉,备用,这样使莼菜提取物、赤石脂纳米粉、硫酸镁混合均匀,避免不均匀导致的局部有效成分含量过大;
步骤二:将所述重量组份的对香豆酸、柚皮苷、荷莲豆素、杧果甙、柠檬烯、桉油精、绿原酸、盐酸左旋咪唑、山梨酸钾、混合氨基酸混合后,再加入步骤一制备的混合粉,置于搅拌机以135r/min,搅拌37.5min,即制得用于胆管炎术后护理的药物组合物;
步骤三:给步骤二制备的药物组合物加入辅料:润滑剂、崩解剂,通过制粒、干燥、整粒、混合、压片、包装制成片剂,所述的润滑剂是硬脂酸镁,所述的崩解剂是低取代羟丙基纤维素。
实施例3:
一种用于胆管炎术后护理的药物组合物的片剂,主要是由以下重量份的成分组成:对香豆酸30份、柚皮苷32份、荷莲豆素28份、莼菜提取物25份、杧果甙26份、赤石脂纳米粉18份、柠檬烯24份、桉油精28份、绿原酸20份、盐酸左旋咪唑12份、硫酸镁溶液40份、玉米浆100份、山梨酸钾16份、混合氨基酸25份。
其中,所述的莼菜提取物制备方法为:将新鲜的莼菜清洗干净后粉碎,置于闪式提取器中,加入8倍量的质量浓度为65%乙醇溶液,进行闪式提取,将得到的提取液静置12h后,经过大孔吸附树脂过滤,将滤液减压浓缩回收乙醇后制得浸膏,再将浸膏使用喷雾干燥塔干燥,即得到莼菜提取物,莼菜中含有淀粉、蛋白质、脂肪、碳水化合物,其中大多为多糖、钙、磷、铁、铜、钾等矿物质元素,以及人体必需的多种氨基酸,对促进人体生长,增加胃液分泌,滋养血液,安神养心,防止肝脏损坏等,均有一定疗效。莼菜多糖是一种酸性果多糖,由岩藻糖、阿拉伯糖、木糖、甘露糖,半乳糖和葡萄糖醛酸组成,是一种较好的免疫促进剂。所述赤石脂纳米粉制备方法为:将赤石脂清洗干净,除去杂质,打碎后研磨成细粉,加入食醋搅拌和匀,搓成直径3cm的条状物,再切成10cm长的小段,常温凉干后置于炉火或坩锅内煅红透,再粉碎后冷却,置于纳米粉碎机粉碎至100nm的细粉,即得到赤石脂纳米粉,主要成分是四水硅酸铝,具有涩肠,止血,生肌敛疮之功效,常用于久泻久痢,大便出血,崩漏带下,可以有效扩张肠道活性。所述混合氨基酸是由蛋氨酸、赖氨酸、苯丙氨酸按照重量比1:3:5组成的混合物,蛋氨酸可以促进肝细胞膜磷脂甲基化,可以减少肝细胞内胆汁的淤积,加强了解毒作用,有利于肝细胞恢复正常生理功能,抵抗各种原因引起的肝内胆汁淤积病毒感染、妊娠和长期肠道外营养都有可能导致肝内胆汁淤积;赖氨酸能促进人体发育、增强免疫功能,并有提高中枢神经组织功能的作用;苯丙氨酸属芳香族氨基酸,在体内大部分经苯丙氨酸羟化酶催化作用氧化成酪氨酸,并与酪氨酸一起合成重要的神经递质和激素,参与机体糖代谢和脂肪代谢;这三种氨基酸混合后能快速的促进肌体恢复,并且增强免疫能力。所述玉米浆中的固体物质含量为70%,玉米浆中含有丰富的可溶性蛋白、生长素和一些前体物质。所述硫酸镁溶液浓度为5%,硫酸镁水溶液到达肠腔后,具有一定渗透压,使肠内水分不被肠壁吸收,肠内保有大量水分,能机械地刺激肠的蠕动,同时会刺激十二指肠粘膜,反射性地引起总胆管括约肌松弛、胆囊收缩,从而促进胆囊排空,有利胆之功效。
一种用于胆管炎术后护理的药物组合物制备方法为:
步骤一:给所述重量组份的玉米浆和硫酸镁溶液混合,再加入所述重量组份的莼菜提取物、赤石脂纳米粉,搅拌均匀,喷雾干燥后得到混合粉,备用,这样使莼菜提取物、赤石脂纳米粉、硫酸镁混合均匀,避免不均匀导致的局部有效成分含量过大;
步骤二:将所述重量组份的对香豆酸、柚皮苷、荷莲豆素、杧果甙、柠檬烯、桉油精、绿原酸、盐酸左旋咪唑、山梨酸钾、混合氨基酸混合后,再加入步骤一制备的混合粉,置于搅拌机以150r/min,搅拌45min,即制得用于胆管炎术后护理的药物组合物;
步骤三:给步骤二制备的药物组合物加入辅料:润滑剂、崩解剂,通过制粒、干燥、整粒、混合、压片、包装制成片剂,所述的润滑剂是滑石粉,所述的崩解剂是交联羧甲基纤维素钠。
本发明药物组合物在治疗Ⅱ型糖尿病中的应用:
一、动物毒性试验:
试验材料:选取实验小鼠60只,体重30-50g。药物:本发明药物组合物l。
实验方法:将小鼠随机分成4组,每组15只,将本药物组合物加生理盐水溶解,配成最大浓度,在小鼠禁食不禁水24h后,每日给药3次,每次1.2g,连续给药三天,观察小鼠的变化。
试验结果:给药后观察一周天,小鼠无一死亡,主要器官未见异常,亦未见其它明显异常,第8天处死并剖检部分小鼠,肉眼观察主要脏器,未见异常。即选用相当于临床剂量的200倍药量,并无不良反应发生。
三个月长期毒性试验:给药期间每周称体重一次,每日称食量,无死亡或濒死动物,结果小鼠毛色光洁,行为活动、腺体分泌、呼吸、粪便性状均正常。病理检查提示,对各种脏器无明显药物所致病理改变。
二、临床试验:治疗效果验证:
1、病例选择:
临床选择300例急性胆管炎手术患者,其中男性162人,女性148人,年龄范围19岁-72岁,随机分为试验组1、试验组2、试验组3、对照组和空白对照组五个组,每组患者在性别、年龄、病程、病情等方面无明显差异,具有可比性。
2、治疗方法:
试验组1、试验组2、试验组3患者分别服用本发明实施例1、2、3制备的片剂每次1.5g,一日3次,7日为一个疗程。
空白组患者常规的广谱抗生素、抗感染药。胃肠减压、解痉镇痛、静脉补液、纠正水电解质紊乱及酸碱平衡、营养支持。
对照组患者在空白组治疗方法的基础上服用消炎利胆片,同时给予营养支持。
3、康复评定指标:
(1)腹痛、发热、黄疸等临床症状消失,患者各项体征正常;
(2)血清ALP水平下降、肝功能的改善;
(3)体内炎症消失,感染消除。
4、试验结果统计:
组别 | 病例数量 | 平均康复时间(天) | 出现副作用病例 | 半年内复发病例 |
试验组1 | 60 | 10 | 0 | 2 |
试验组2 | 60 | 7 | 0 | 0 |
试验组3 | 60 | 9 | 0 | 1 |
空白组 | 60 | 16 | 8 | 6 |
对照组 | 60 | 14 | 12 | 5 |
综上所述,本发明制备的药物组合物对胆管炎术后恢复有很好的促进作用,且暂未发现有任何副作用,有很好的临床效果。
尽管已参照其具体实施方案描述和阐明了本发明,但本领域技术人员会认识到,可以在不背离本发明的精神和范围的情况下对其作出各种改变、修改和取代。例如,由于被治疗特定病症的人的响应能力的变化,如上阐述的优选剂量以外的有效剂量可能适用。同样地,观察到的药理学响应可能根据和依赖所选特定活性化合物或是否存在药用载体以及制剂类型和所用给药模式而变,根据本发明的目的和实践预想到结果中的这类预期变化或差异。因此,本发明意在仅受下列权利要求的范围限制且这些权利要求应在合理的程度上尽可能广义地解释。
Claims (10)
1.一种用于胆管炎术后护理的药物组合物,其特征在于,是由以下重量份的成分组成:对香豆酸12-30份、柚皮苷15-32份、荷莲豆素10-28份、莼菜提取物10-25份、杧果甙15-26份、赤石脂纳米粉8-18份、柠檬烯12-24份、桉油精16-28份、绿原酸14-20份、盐酸左旋咪唑6-12份、硫酸镁溶液20-40份、玉米浆50-100份、山梨酸钾8-16份、混合氨基酸13-25份。
2.如权利要求1所述的一种用于胆管炎术后护理的药物组合物,其特征在于,所述的莼菜提取物制备方法为:将新鲜的莼菜清洗干净后粉碎,置于闪式提取器中,加入5-8倍量的质量浓度为55-65%乙醇溶液,进行闪式提取,将得到的提取液静置8-12h后,经过大孔吸附树脂过滤,将滤液减压浓缩回收乙醇后制得浸膏,再将浸膏使用喷雾干燥塔干燥,即得到莼菜提取物。
3.如权利要求1所述的一种用于胆管炎术后护理的药物组合物,其特征在于,所述赤石脂纳米粉制备方法为:将赤石脂清洗干净,除去杂质,打碎后研磨成细粉,加入食醋搅拌和匀,搓成直径2-3cm的条状物,再切成8-10cm长的小段,常温凉干后置于炉火或坩锅内煅红透,再粉碎后冷却,置于纳米粉碎机粉碎至50-100nm的细粉,即得到赤石脂纳米粉。
4.如权利要求1所述的一种用于胆管炎术后护理的药物组合物,其特征在于,所述混合氨基酸是由蛋氨酸、赖氨酸、苯丙氨酸组成的混合物。
5.如权利要求1所述的一种用于胆管炎术后护理的药物组合物,其特征在于,所述玉米浆中的固体物质含量为50-70%。
6.如权利要求1所述的一种用于胆管炎术后护理的药物组合物,其特征在于,所述硫酸镁溶液浓度为3-5%。
7.如权利要求1所述的一种用于胆管炎术后护理的药物组合物,,其特征在于制备方法为:
步骤一:给所述重量组份的玉米浆和硫酸镁溶液混合,再加入所述重量组份的莼菜提取物、赤石脂纳米粉,搅拌均匀,喷雾干燥后得到混合粉,备用;
步骤二:将所述重量组份的对香豆酸、柚皮苷、荷莲豆素、杧果甙、柠檬烯、桉油精、绿原酸、盐酸左旋咪唑、山梨酸钾、混合氨基酸混合后,再加入步骤一制备的混合粉,置于搅拌机以120-150r/min,搅拌30-45min,即制得用于胆管炎术后护理的药物组合物。
8.如权利要求7所述的一种用于胆管炎术后护理的药物组合物,其特征在于给所述的药物组合物中加入辅料:润滑剂、崩解剂,通过制粒、干燥、整粒、混合、压片、包装制成片剂。
9.如权利要求8所述的一种用于胆管炎术后护理的药物组合物,其特征在于所述的润滑剂是微粉硅胶、硬脂酸镁、滑石粉的一种或者几种混合。
10.如权利要求8所述的一种用于胆管炎术后护理的药物组合物,其特征在于所述的崩解剂是羧甲基淀粉钠、低取代羟丙基纤维素、交联羧甲基纤维素钠的一种或者几种混合。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610049845.9A CN105582382A (zh) | 2016-01-25 | 2016-01-25 | 一种用于胆管炎术后护理的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610049845.9A CN105582382A (zh) | 2016-01-25 | 2016-01-25 | 一种用于胆管炎术后护理的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105582382A true CN105582382A (zh) | 2016-05-18 |
Family
ID=55922531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610049845.9A Pending CN105582382A (zh) | 2016-01-25 | 2016-01-25 | 一种用于胆管炎术后护理的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105582382A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109172561A (zh) * | 2018-08-21 | 2019-01-11 | 广州中医药大学(广州中医药研究院) | 防治流感病毒的药物组合物 |
CN110885270A (zh) * | 2019-12-16 | 2020-03-17 | 中国热带农业科学院农产品加工研究所 | 一种植物酶响应性控释肥、纳米载体及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103495067A (zh) * | 2013-10-15 | 2014-01-08 | 班晓杰 | 一种用于狭窄性胆管炎外科分流术后使用的药物组合物 |
CN103566267A (zh) * | 2013-11-15 | 2014-02-12 | 张�杰 | 一种用于重症肝内胆管结石术后护理的药物及制备方法 |
CN105106499A (zh) * | 2015-09-06 | 2015-12-02 | 江淑芬 | 一种用于狭窄性胆管炎外科分流术后使用的中药组合物 |
-
2016
- 2016-01-25 CN CN201610049845.9A patent/CN105582382A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103495067A (zh) * | 2013-10-15 | 2014-01-08 | 班晓杰 | 一种用于狭窄性胆管炎外科分流术后使用的药物组合物 |
CN103566267A (zh) * | 2013-11-15 | 2014-02-12 | 张�杰 | 一种用于重症肝内胆管结石术后护理的药物及制备方法 |
CN105106499A (zh) * | 2015-09-06 | 2015-12-02 | 江淑芬 | 一种用于狭窄性胆管炎外科分流术后使用的中药组合物 |
Non-Patent Citations (1)
Title |
---|
张朝柱等: "内镜下鼻胆管引流术联合中药治疗急性梗阻性化脓性胆管炎的疗效观察", 《临床消化病杂志》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109172561A (zh) * | 2018-08-21 | 2019-01-11 | 广州中医药大学(广州中医药研究院) | 防治流感病毒的药物组合物 |
CN110885270A (zh) * | 2019-12-16 | 2020-03-17 | 中国热带农业科学院农产品加工研究所 | 一种植物酶响应性控释肥、纳米载体及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102698123B (zh) | 治疗猪传染性胃肠炎的中药组合物、饲料、制备和应用 | |
CN101103811A (zh) | 一种通便的保健食品 | |
CN105166545A (zh) | 一种牛配合饲料及其制备方法 | |
CN102743657B (zh) | 防治仔猪腹泻病的中药物组合物及其制备方法 | |
CN105582382A (zh) | 一种用于胆管炎术后护理的药物组合物及其制备方法 | |
CN102526639B (zh) | 治疗高血脂症的中药组合物及其制备方法 | |
CN101700296B (zh) | 一种治疗肠胃炎的中药制剂及其制备方法 | |
CN108014301A (zh) | 一种治疗白血病的中药酵素及其制备方法 | |
CN100453099C (zh) | 一种治疗妇女盆腔炎的制剂及其制备方法 | |
CN103719616B (zh) | 用于治疗猪血痢的饲料及其制备方法 | |
CN109646546B (zh) | 一种用于防治牲畜腹泻的中药组合物及其制备方法 | |
CN106038975A (zh) | 一种具有止咳作用的中药组合物及其制备方法与用途 | |
CN107551280A (zh) | 一种适用于肠道菌群失衡患者的消化道超声造影剂 | |
CN105902760B (zh) | 一种治疗兔胃肠炎的中药 | |
CN104434950A (zh) | 一种治疗结肠癌的杜仲靶向制剂及其制备方法 | |
CN101007136A (zh) | 一种新的清热解毒软胶囊的制备工艺 | |
CN103041160B (zh) | 用于治疗急性咽炎的中药组合物及其制备方法 | |
CN1217679C (zh) | 通便贴敷散 | |
CN103191243A (zh) | 由黄连、吴茱萸组成的药物组合物的用途及其制备方法 | |
CN116942771B (zh) | 一种治疗冠心病的中药组合物及其应用 | |
CN107913402A (zh) | 一种治疗萎缩性胃炎的中西医结合药物及制备方法 | |
CN100542600C (zh) | 一种治疗腹泻的药物组合物及其制备方法和用途 | |
CN106822162A (zh) | 人参皂苷Rg3急性心梗的治疗作用 | |
CN105412803B (zh) | 治疗家禽腺胃炎的药物组合物及其制备方法 | |
CN105396107A (zh) | 一种治疗肠胃炎的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160518 |